Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QGC001 in Chronic Heart Failure (QUID-HF)
NCT02780180Phase 2Terminated
- Sponsor
- Quantum Genomics
- Start
- Jun 2016
- Primary completion
- Sep 2018
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial in chronic heart failure (CHF) comparing QGC001 with Placebo (2 arms). Primary endpoints: Relative decrease in NT-proBNP at 28 days and Blood pressure change at 28 days. Started Jun 2016; status: terminated.
02
Drugs
firibastat
03
Conditions
chronic heart failure (CHF)
Beyond the preview
Go deeper on NCT02780180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02780180.